Five things for pharma marketers to know: Wednesday, August 24, 2016

Nancy Retzlaff (left), chief commercial officer at Turing, and Martin Shrekli (right), the then CEO of Turing, prepare to testify at a House hearing in February. 

1. Nancy Retzlaff, Turing Pharmaceuticals' chief commercial officer, filed a complaint that accuses Edwin Urrutia, Turing's co-founder, of sexually assaulting her. In her complaint, Retzlaff also said that company leaders retaliated against her after Urrutia resigned and that she was denied the role of CEO after Martin Shkreli departed. (NYT)

2. Pfizer said it will buy part of AstraZeneca's antibiotics business for about $1.5 billion. Pfizer, which earlier this week acquired Medivation for $14 billion, will gain the rights to three antibiotics and two drugs in development. (WSJ)

3. EpiPen's price hikes are under criticism. So are Mylan's marketing tactics, which included hiring actress Sarah Jessica Parker for an awareness campaign as well as encouraging public schools to carry the product. (Gizmodo)

4. Hundreds of pharmaceutical and medical device companies continue to use physicians as promotional speakers even after they have been disciplined for misconduct. At least 2,300 doctors who received payments from drug or device makers between August 2013 and December 2015 had histories of misconduct. (ProPublica)

5. The use of patents in the U.S. is one of the most important factors in prescription drug costs, according to researchers at Harvard Medical School. Pay-for-delay deals stall the arrival of competition for up to 20 years. (Kaiser Health News)